Health Care & Life Sciences » Biotechnology | Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
1.60
37.90
53.50
77.50
55.90
50.70
Gross Income
1.60
37.90
53.50
77.50
55.90
50.70
SG&A Expense
6,586.20
22,442.60
24,776.30
26,770.00
26,854.90
23,776.60
EBIT
6,587.80
22,480.50
24,829.80
26,847.50
26,910.80
23,827.30
Unusual Expense
4,179.40
2,206.10
3,812.30
2,530.80
304.10
-
Non Operating Income/Expense
4.10
-
-
-
-
-
Interest Expense
2.50
0.90
7.90
5.00
-
-
Pretax Income
10,773.80
24,687.50
21,025.30
24,321.70
26,601.20
23,654
Consolidated Net Income
10,773.80
24,687.50
21,025.30
24,321.70
26,601.20
23,654
Net Income
10,773.80
24,687.50
21,025.30
24,321.70
26,601.20
23,654
Net Income After Extraordinaries
10,773.80
24,687.50
21,025.30
24,321.70
26,601.20
23,654
Net Income Available to Common
10,773.80
24,687.50
21,025.30
24,321.70
26,601.20
23,654
EPS (Basic)
0.47
0.90
0.55
0.50
0.40
0.22
Basic Shares Outstanding
22,752.80
27,363.70
38,158.50
48,463.30
66,746.40
106,041.80
EPS (Diluted)
0.47
0.90
0.55
0.50
0.40
0.22
Diluted Shares Outstanding
22,752.80
27,363.70
38,158.50
48,463.30
66,746.40
106,041.80
EBITDA
6,586.20
22,442.60
24,776.30
26,770.00
26,854.90
23,776.60
Non-Operating Interest Income
-
-
-
-
5.40
173.40

About Actinium Pharmaceuticals

View Profile
Address
275 Madison Avenue
New York New York 10016
United States
Employees -
Website http://www.actiniumpharmaceuticals.com
Updated 07/08/2019
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.